Prazer Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $32.8M

  • Investors
  • 19

Prazer Therapeutics General Information

Description

Operator of a biotechnology company intended to develop novel therapeutics to treat a variety of refractory diseases. The company is focused on developing therapeutics for the treatment of neurodegenerative diseases and refractory inflammatory diseases using next-generation protein degradation technology, enabling the healthcare industry to focus on the advancement of novel drugs in areas of unmet medical need.

Contact Information

Website
www.prazertx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 306, 3rd floor, Global Center Building, 117-3 Hoegi-ro
  • Hoegi-dong, Seoul Bio Hub, Dongdaemun-gu
  • Seoul, 02455
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 306, 3rd floor, Global Center Building, 117-3 Hoegi-ro
  • Hoegi-dong, Seoul Bio Hub, Dongdaemun-gu
  • Seoul, 02455
  • South Korea
+82

Prazer Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prazer Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 16-Jul-2026 $32.8M Completed Generating Revenue
6. Later Stage VC (Series B) 09-Mar-2025 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 23-Nov-2020 Completed Pre-Clinical Trials
4. Accelerator/Incubator 01-Jun-2020 Completed Pre-Clinical Trials
3. Seed Round 31-Dec-2019 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Prazer Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Prazer Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop novel therapeutics to treat a variety of refractory diseases. Th
Drug Discovery
Seoul, South Korea
25 As of 2026

New Haven, CT
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prazer Therapeutics Competitors (3)

One of Prazer Therapeutics’s 3 competitors is Arvinas, a Formerly VC-backed company based in New Haven, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arvinas Formerly VC-backed New Haven, CT
Kymera Therapeutics Formerly VC-backed Watertown, MA
Amphista Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

Prazer Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prazer Therapeutics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hana Securities PE/Buyout Minority
Mirae Asset Securities Investment Bank Minority
Playground Global Venture Capital Minority
Shinhan Asset Management Asset Manager Minority
Woori Venture Partners Venture Capital Minority
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial

Prazer Therapeutics FAQs

  • When was Prazer Therapeutics founded?

    Prazer Therapeutics was founded in 2019.

  • Where is Prazer Therapeutics headquartered?

    Prazer Therapeutics is headquartered in Seoul, South Korea.

  • What is the size of Prazer Therapeutics?

    Prazer Therapeutics has 25 total employees.

  • What industry is Prazer Therapeutics in?

    Prazer Therapeutics’s primary industry is Drug Discovery.

  • Is Prazer Therapeutics a private or public company?

    Prazer Therapeutics is a Private company.

  • What is Prazer Therapeutics’s current revenue?

    The current revenue for Prazer Therapeutics is .

  • How much funding has Prazer Therapeutics raised over time?

    Prazer Therapeutics has raised $68.6M.

  • Who are Prazer Therapeutics’s investors?

    Hana Securities, Mirae Asset Securities, Playground Global, Shinhan Asset Management, and Woori Venture Partners are 5 of 19 investors who have invested in Prazer Therapeutics.

  • Who are Prazer Therapeutics’s competitors?

    Arvinas, Kymera Therapeutics, and Amphista Therapeutics are competitors of Prazer Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process